"Of-course the Spin off will devalue the value of ACL, the SP will take a massive hit. Oncology will need lots of funding so it could take most of what Fonda has generated with it- Plus there will be an IPO"
I disagree with you Neo. I also think you will be far better "selling out" after the split.
The oncology company will probably take the bulk of acl's cash, so maybe $20m. A further $10m may also be raised. There's then the options, which could bring in another $5m.
So there's around $35m, which is more than enough to get the phase 3 done and dusted.
Assuming that HyACT proves to be successful (which all evidence to date suggests it will). Then we have a multi product proven technology. Any further trials (if not sponser funded) will easily attract partnerships. Of course success would also mean that income will start flow in within a few years too!
So with all that potential and enough cash to finish the trial, I can imagine the market giving oncology a valuation of at least $200m (some months after the split). They will be ripe for takeover potential too!
all imho, cheers
ps. I think you are being too negative. didn't you say sell at around 34c a few weeks back?
- Forums
- ASX - By Stock
- what announcement next
"Of-course the Spin off will devalue the value of ACL, the SP...
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable